News stories about Omnicell (NASDAQ:OMCL) have trended somewhat positive this week, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Omnicell earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.7455914399182 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:

A number of brokerages have recently issued reports on OMCL. Cantor Fitzgerald raised their price objective on Omnicell to $58.00 and gave the company an “overweight” rating in a research note on Friday, October 27th. Oppenheimer reaffirmed a “buy” rating and set a $55.00 price objective on shares of Omnicell in a research note on Thursday, October 19th. Benchmark raised their price objective on Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, September 5th. Craig Hallum reaffirmed a “buy” rating and set a $62.00 price objective (up from $52.00) on shares of Omnicell in a research note on Monday, October 30th. Finally, Zacks Investment Research cut Omnicell from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $55.14.

Shares of Omnicell (NASDAQ:OMCL) opened at $51.75 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.08 and a current ratio of 1.53. Omnicell has a 1-year low of $31.85 and a 1-year high of $55.40.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, October 26th. The company reported $0.42 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.42. The company had revenue of $186.78 million during the quarter, compared to analyst estimates of $192.45 million. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. Omnicell’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.40 earnings per share. sell-side analysts forecast that Omnicell will post 0.12 earnings per share for the current fiscal year.

In other news, EVP Dan S. Johnston sold 14,613 shares of the stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $47.81, for a total transaction of $698,647.53. Following the completion of the sale, the executive vice president now directly owns 43,621 shares in the company, valued at $2,085,520.01. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Peter J. Kuipers sold 4,724 shares of the stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $47.74, for a total transaction of $225,523.76. Following the sale, the vice president now owns 40,544 shares of the company’s stock, valued at $1,935,570.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,164 shares of company stock valued at $1,410,666. 3.77% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Omnicell (OMCL) Stock Price” was published by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-omnicell-omcl-stock-price/1766953.html.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Insider Buying and Selling by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.